Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the… Read more
Longboard Pharmaceuticals Inc (LBPH) - Total Liabilities
Latest total liabilities as of September 2024: $21.82 Million USD
Based on the latest financial reports, Longboard Pharmaceuticals Inc (LBPH) has total liabilities worth $21.82 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Longboard Pharmaceuticals Inc - Total Liabilities Trend (2020–2023)
This chart illustrates how Longboard Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Longboard Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Longboard Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Antong Holdings Co Ltd
SHG:600179
|
China | CN¥3.30 Billion |
|
Region Group
AU:RGN
|
Australia | AU$1.81 Billion |
|
O-I Glass Inc
NYSE:OI
|
USA | $6.93 Billion |
|
X Trade Brokers Dom Maklerski SA
WAR:XTB
|
Poland | zł6.51 Billion |
|
Gland Pharma Limited
NSE:GLAND
|
India | ₹22.37 Billion |
|
Sharp Corporation
PINK:SHCAF
|
USA | $1.17 Trillion |
|
Universal Technical Institute Inc
NYSE:UTI
|
USA | $498.03 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Longboard Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Longboard Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Longboard Pharmaceuticals Inc (2020–2023)
The table below shows the annual total liabilities of Longboard Pharmaceuticals Inc from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $9.77 Million | +6.87% |
| 2022-12-31 | $9.15 Million | +62.48% |
| 2021-12-31 | $5.63 Million | +79.55% |
| 2020-12-31 | $3.13 Million | -- |